Tirzepatide pens contain LY3298176, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative peptide demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
Our tirzepatide pens are manufactured under strict pharmaceutical standards, providing researchers with consistent, high-quality material for diabetes and metabolic disorder studies. The compound shows particular promise in type 2 diabetes treatment research.
The molecular mechanism of tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, with preferential binding to GIP receptors. This unique dual agonist activity results in enhanced glycemic control and significant weight reduction effects in preclinical models.
For laboratory use only. Not for human consumption. All tirzepatide pens are supplied for research purposes exclusively.